1. MIPS Value Pathways (MVP)
1.1. No new eCQMs proposed
2. Looking Ahead to 2026
2.1. MVP's are the Future 2026+
3. Review of Available Resources
3.1. CMS Proposed Rule: 88 FR 52262
3.2. Proposed Modified MIPS Value Pathways
3.3. QPP Proposed Rule Fact Sheet and Policy Comparison Table
3.4. NOT AVAILABLET YET: 2024 Quality Payment Program Final Rule Resources
4. Traditional MIPS Requirement Categories
4.1. Quality
4.1.1. Collection Types
4.1.1.1. eCQMS (ONC-certified technology calculated)
4.1.1.1.1. NEW: Quality Measures Proposed for the CY 2024 Performance Period/2026 MIPS Payment Year and Future Years
4.1.1.1.2. REMOVED: Quality Measure Removals Proposed for the CY 2024 Performance Period/2026 MIPS Payment Year and Future Years
4.1.1.1.3. REMOVED MIPS /RETAINED MVP: Removals from Traditional MIPS (Retained for MVPs) Proposed for the CY 2024 Performance Period/2026 MIPS Payment Year and Future Years
4.1.1.2. CQMS (non-certified data)
4.1.1.2.1. Quite a few changes
4.1.1.3. QCDR
4.1.1.4. Medicare Part B Claims Measures
4.1.1.5. CAHPS for MIPS Survey
4.2. Promoting Interoperability (PI)
4.2.1. CEHRT Requirements (NO AFFECT on Developers
4.2.1.1. We’re proposing to update the CEHRT definition to align with the Office of the National Coordinator for Health IT (ONC)’s regulations. Removal of year "edition" designators
4.2.2. Performance Period
4.2.2.1. Change from minimum continuous measurement period in calendar year from 90 days to 190 days
4.2.3. Measures
4.2.3.1. Query of Prescription Drug Monitoring Program (PDMP) Measure Exclusion
4.2.3.1.1. We’re proposing to modify this exclusion to the following: • “Does not electronically prescribe any Schedule II opioids or Schedule III or IV drugs during the performance period.” The current exclusion is too broad and doesn’t necessarily accommodate clinicians who don’t electronically prescribe any Schedule II opioids and Schedule III and IV drugs during the performance period.
4.2.4. Measure Points
4.2.4.1. Safety Assurance Factors for EHR Resilience (SAFER) Guides Measure
4.2.4.1.1. We’re proposing to require a “yes” response for the SAFER Guide measure beginning with the CY 2024 performance period. • Clinicians only need to review the High Priority Practices SAFER guide.
4.2.5. Third Party Intermediaries
4.2.5.1. We’re proposing to eliminate the health IT vendor category of third party intermediaries, beginning with the CY 2025 performance period, to remove gaps in third party intermediary requirements and improve data integrity. In order to submit data on behalf of clinicians, a health IT vendor would need to meet the requirements of and self-nominate to become a qualified registry or QCDR. They can continue to facilitate data collection and support clinicians and groups in the sign in and upload
4.3. Improvement Activities
4.3.1. Changes, but NO AFFECT on Developers
4.4. Cost
4.4.1. Changes, but NO AFFECT on Developers